X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GSK PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GSK PHARMA NOVARTIS/
GSK PHARMA
 
P/E (TTM) x 425.8 48.9 870.4% View Chart
P/BV x 30.0 9.7 309.0% View Chart
Dividend Yield % 1.5 1.6 93.5%  

Financials

 NOVARTIS   GSK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
GSK PHARMA
Mar-19
NOVARTIS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7583,595 21.1%   
Low Rs5791,253 46.2%   
Sales per share (Unadj.) Rs228.4184.7 123.7%  
Earnings per share (Unadj.) Rs31.726.3 120.7%  
Cash flow per share (Unadj.) Rs32.829.2 112.3%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.50.8 181.3%  
Book value per share (Unadj.) Rs297.1126.3 235.2%  
Shares outstanding (eoy) m24.69169.40 14.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.913.1 22.3%   
Avg P/E ratio x21.192.2 22.8%  
P/CF ratio (eoy) x20.483.1 24.5%  
Price / Book Value ratio x2.219.2 11.7%  
Dividend payout %31.576.1 41.4%   
Avg Mkt Cap Rs m16,505410,626 4.0%   
No. of employees `0000.75.0 13.5%   
Total wages/salary Rs m1,4455,372 26.9%   
Avg. sales/employee Rs Th8,441.36,306.7 133.8%   
Avg. wages/employee Rs Th2,163.61,083.1 199.8%   
Avg. net profit/employee Rs Th1,173.1898.0 130.6%   
INCOME DATA
Net Sales Rs m5,63931,281 18.0%  
Other income Rs m1,7181,023 167.9%   
Total revenues Rs m7,35732,304 22.8%   
Gross profit Rs m-636,009 -1.0%  
Depreciation Rs m25486 5.2%   
Interest Rs m556 921.7%   
Profit before tax Rs m1,5756,540 24.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m7922,373 33.4%   
Profit after tax Rs m7844,454 17.6%  
Gross profit margin %-1.119.2 -5.8%  
Effective tax rate %50.336.3 138.5%   
Net profit margin %13.914.2 97.6%  
BALANCE SHEET DATA
Current assets Rs m9,52220,061 47.5%   
Current liabilities Rs m3,29614,543 22.7%   
Net working cap to sales %110.417.6 625.9%  
Current ratio x2.91.4 209.4%  
Inventory Days Days3757 64.5%  
Debtors Days Days2814 202.1%  
Net fixed assets Rs m4614,343 0.3%   
Share capital Rs m1231,694 7.3%   
"Free" reserves Rs m7,21319,704 36.6%   
Net worth Rs m7,33621,398 34.3%   
Long term debt Rs m02 0.0%   
Total assets Rs m11,10539,113 28.4%  
Interest coverage x29.51,091.0 2.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 63.5%   
Return on assets %7.611.4 66.2%  
Return on equity %10.720.8 51.3%  
Return on capital %22.231.9 69.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m61534 11.3%   
Fx outflow Rs m3,6307,091 51.2%   
Net fx Rs m-3,570-6,557 54.4%   
CASH FLOW
From Operations Rs m1,6103,994 40.3%  
From Investments Rs m687-1,433 -47.9%  
From Financial Activity Rs m-2,677-3,584 74.7%  
Net Cashflow Rs m-380-1,023 37.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 2.0 10.2 19.6%  
FIIs % 1.6 23.8 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 102,036 40.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  IPCA LABS  ALKEM LABORATORIES  

Compare NOVARTIS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Related Views on News

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 24, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS